Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar.

< BACK TO ARCHIVE


2019


Reumatologia


http://www.ncbi.nlm.nih.gov/pubmed/31853152?dopt=Abstract


57


5

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar.

Authors

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar.
Felis-Giemza A, Chmurzyńska K, Nałęcz-Janik J, Romanowska-Próchnicka K, Świerkocka K, Wudarski M, Olesińska M
Reumatologia. 2019; 57(5):257-263.
PMID: 31853152.

Abstract

The aim of the study was to assess the safety and efficacy of switching an etanercept originator to an etanercept biosimilar in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients.
Read This Paper